Browse ADRA2C

Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0006939 smooth muscle contraction
GO:0006940 regulation of smooth muscle contraction
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007176 regulation of epidermal growth factor-activated receptor activity
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007189 adenylate cyclase-activating G-protein coupled receptor signaling pathway
GO:0007565 female pregnancy
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008015 blood circulation
GO:0009306 protein secretion
GO:0009914 hormone transport
GO:0010469 regulation of receptor activity
GO:0010700 negative regulation of norepinephrine secretion
GO:0010720 positive regulation of cell development
GO:0010817 regulation of hormone levels
GO:0014060 regulation of epinephrine secretion
GO:0014061 regulation of norepinephrine secretion
GO:0015833 peptide transport
GO:0015837 amine transport
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0015874 norepinephrine transport
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019229 regulation of vasoconstriction
GO:0019233 sensory perception of pain
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030168 platelet activation
GO:0031644 regulation of neurological system process
GO:0032147 activation of protein kinase activity
GO:0032148 activation of protein kinase B activity
GO:0032811 negative regulation of epinephrine secretion
GO:0033604 negative regulation of catecholamine secretion
GO:0033674 positive regulation of kinase activity
GO:0035150 regulation of tube size
GO:0035624 receptor transactivation
GO:0035625 epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway
GO:0038127 ERBB signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042310 vasoconstriction
GO:0042886 amide transport
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0044057 regulation of system process
GO:0044706 multi-multicellular organism process
GO:0045666 positive regulation of neuron differentiation
GO:0045741 positive regulation of epidermal growth factor-activated receptor activity
GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
GO:0045860 positive regulation of protein kinase activity
GO:0045907 positive regulation of vasoconstriction
GO:0045932 negative regulation of muscle contraction
GO:0045986 negative regulation of smooth muscle contraction
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0048241 epinephrine transport
GO:0048242 epinephrine secretion
GO:0048243 norepinephrine secretion
GO:0050432 catecholamine secretion
GO:0050433 regulation of catecholamine secretion
GO:0050708 regulation of protein secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050769 positive regulation of neurogenesis
GO:0050796 regulation of insulin secretion
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0050880 regulation of blood vessel size
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0051937 catecholamine transport
GO:0051952 regulation of amine transport
GO:0051953 negative regulation of amine transport
GO:0051962 positive regulation of nervous system development
GO:0061097 regulation of protein tyrosine kinase activity
GO:0061098 positive regulation of protein tyrosine kinase activity
GO:0070471 uterine smooth muscle contraction
GO:0070472 regulation of uterine smooth muscle contraction
GO:0070473 negative regulation of uterine smooth muscle contraction
GO:0071875 adrenergic receptor signaling pathway
GO:0071880 adenylate cyclase-activating adrenergic receptor signaling pathway
GO:0071883 activation of MAPK activity by adrenergic receptor signaling pathway
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090066 regulation of anatomical structure size
GO:0090087 regulation of peptide transport
GO:0090257 regulation of muscle system process
GO:0090276 regulation of peptide hormone secretion
GO:1901184 regulation of ERBB signaling pathway
GO:1901186 positive regulation of ERBB signaling pathway
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1903531 negative regulation of secretion by cell
GO:2000273 positive regulation of receptor activity
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004935 adrenergic receptor activity
GO:0004936 alpha-adrenergic receptor activity
GO:0004938 alpha2-adrenergic receptor activity
GO:0008227 G-protein coupled amine receptor activity
GO:0031690 adrenergic receptor binding
GO:0031694 alpha-2A adrenergic receptor binding
GO:0046982 protein heterodimerization activity
GO:0051379 epinephrine binding
GO:1901338 catecholamine binding
Cellular Component GO:0030424 axon
GO:0033267 axon part
GO:0043679 axon terminus
GO:0044306 neuron projection terminus
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-392023: Adrenaline signalling through Alpha-2 adrenergic receptor
R-HSA-400042: Adrenaline,noradrenaline inhibits insulin secretion
R-HSA-390696: Adrenoceptors
R-HSA-375280: Amine ligand-binding receptors
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-418597: G alpha (z) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-109582: Hemostasis
R-HSA-163685: Integration of energy metabolism
R-HSA-1430728: Metabolism
R-HSA-392499: Metabolism of proteins
R-HSA-76009: Platelet Aggregation (Plug Formation)
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-422356: Regulation of insulin secretion
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-5683826: Surfactant metabolism
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADRA2C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADRA2C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADRA2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7370.332
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2290.867
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1240.367
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1250.891
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1620.904
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5030.772
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0980.896
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4390.686
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1990.865
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4310.037
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4720.13
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3410.233
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADRA2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADRA2C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADRA2C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADRA2C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADRA2C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADRA2C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADRA2C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADRA2C
Nameadrenoceptor alpha 2C
Aliases ADRARL2; ADRA2L2; ADRA2RL2; adrenergic, alpha-2C-, receptor; ALPHA2CAR; alpha-2 adrenergic receptor subtype ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADRA2C collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ADRA2C.
ID Name Drug Type Targets #Targets
DB00182AmphetamineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB ......19
DB00217BethanidineSmall MoleculeADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, KCNJ17
DB00246ZiprasidoneSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4 ......25
DB00248CabergolineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1 ......22
DB00268RopiniroleSmall MoleculeADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B ......14
DB00334OlanzapineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1 ......50
DB00363ClozapineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, ......27
DB00368NorepinephrineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB ......12
DB00370MirtazapineSmall MoleculeADRA1A, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, DRD1 ......23
DB00397PhenylpropanolamineSmall MoleculeADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD16
DB00408LoxapineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3 ......34
DB00413PramipexoleSmall MoleculeADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B ......14
DB00477ChlorpromazineSmall MoleculeADRA1A, ADRA1A, ADRA1B, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CH ......31
DB00484BrimonidineSmall MoleculeADRA2A, ADRA2B, ADRA2C3
DB00540NortriptylineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB ......24
DB00543AmoxapineSmall MoleculeADRA1A, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2A, ADRA2B, ADRA2C, CH ......48
DB00575ClonidineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C6
DB00589LisurideSmall MoleculeADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B ......15
DB00668EpinephrineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB ......12
DB00697TizanidineSmall MoleculeADRA2A, ADRA2B, ADRA2C, NISCH4
DB00714ApomorphineSmall MoleculeADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, ......15
DB00734RisperidoneSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HR ......15
DB00797TolazolineSmall MoleculeADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH26
DB00800FenoldopamSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD58
DB00841DobutamineSmall MoleculeADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ESR16
DB00925PhenoxybenzamineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB27
DB00934MaprotilineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......17
DB00935OxymetazolineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C6
DB01049Ergoloid mesylateSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, GABRA1 ......41
DB01136CarvedilolSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, GJA1 ......17
DB01142DoxepinSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......23
DB01151DesipramineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM ......21
DB01186PergolideSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, ......17
DB01200BromocriptineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, ......18
DB01224QuetiapineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......26
DB01238AripiprazoleSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4 ......25
DB01267PaliperidoneSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DR ......18
DB01363EphedraSmall MoleculeADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, MAOA, MAOB, SLC18A1, ......13
DB01365MephentermineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB ......9
DB01392YohimbineSmall MoleculeADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR2A, HT ......18
DB01403MethotrimeprazineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......19
DB01577MethamphetamineSmall MoleculeADRA2A, ADRA2B, ADRA2C, MAOA, MAOB, SLC18A1, SLC18A2, SLC6A2, SLC6 ......11
DB04855DronedaroneSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CA ......18
DB04946IloperidoneSmall MoleculeADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, ......11
DB05461OPC-28326Small MoleculeADRA2B, ADRA2C, HTR2B3
DB05492Epicept NP-1Small MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HRH1, HTR2A, HTR2B ......12
DB06148MianserinSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, ......23
DB06216AsenapineSmall MoleculeADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DR ......20
DB06229OcaperidoneSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD2, HRH1, HTR2A, ......11
DB06262DroxidopaSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB ......10
DB06678EsmirtazapineSmall MoleculeADRA2A, ADRA2B, ADRA2C, HRH1, HTR2A, HTR2B, HTR2C7
DB06694XylometazolineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C6
DB06707LevonordefrinSmall MoleculeADRA2A, ADRA2B, ADRA2C3
DB08815LurasidoneSmall MoleculeADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR76
DB08838AgmatineSmall MoleculeADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH7
DB09128BrexpiprazoleSmall MoleculeADRA1B, ADRA2C, DRD2, HTR1A, HTR2A5
DB09167DosulepinSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......16
DB09194EtoperidoneSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......15
DB09195LorpiprazoleSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HRH1, HTR2A, HTR2C ......10
DB09202CirazolineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C6
DB09205MoxisylyteSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C6
DB09229AranidipineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D, ......10
DB09304SetiptilineSmall MoleculeADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, ......19
DB11124RacepinephrineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB27
DB13025TiaprideSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HRH1, ......25